JO
ARTV

John Overdeck’s Artiva Biotherapeutics ARTV Stock Holding History

John Overdeck’s Portfolio ARTV Stock Details ARTV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$762K Sell
78,575
-36,466
-32% -$332K ﹤0.01% 3825
2026
Q1 		$741K Sell
115,041
-29,823
-21% -$148K ﹤0.01% 3460
2025
Q4 		$621K Buy
144,864
+124,500
+611% +$470K ﹤0.01% 3195
2025
Q3 		$58.4K Sell
20,364
-1,007
-5% -$2.69K ﹤0.01% 3527
2025
Q2 		$32.3K Buy
+21,371
New +$44.9K ﹤0.01% 3097

Other funds holding ARTV

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return

John Overdeck's ARTV Position: Q2 2026 in Review

John Overdeck reduced its Artiva Biotherapeutics (ARTV) stake by 32% in Q2 2026, selling an estimated $332K and leaving 78,575 shares worth $762K. The position accounts for ﹤0.01% of the portfolio, ranked #3825.

John Overdeck first reported a position in ARTV in Q2 2025 and has held it in 5 quarters since. 72 funds tracked by Wall St. Rank hold ARTV as of Q2 2026.

  • John Overdeck held 78,575 shares of Artiva Biotherapeutics worth $762K as of Q2 2026.
  • John Overdeck sold 36,466 Artiva Biotherapeutics shares in Q2 2026, an estimated $332K.
  • Artiva Biotherapeutics made up ﹤0.01% of John Overdeck's portfolio in Q2 2026, its #3825 holding.
  • John Overdeck first reported a position in Artiva Biotherapeutics in Q2 2025 and has held it in 5 quarters since.
  • 72 funds tracked by Wall St. Rank held Artiva Biotherapeutics as of Q2 2026.

Based on Two Sigma Investments's 13F filing for Q2 2026, filed 14 Aug 2026.